Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

PRO-542

Known as: PRO 542 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2008
Highly Cited
2008
The small molecule CCR5 inhibitors are a new class of drugs for treating infection by human immunodeficiency virus type 1 (HIV-1… Expand
Highly Cited
2004
Highly Cited
2004
Identification of cellular factors involved in HIV-1 entry and transmission at mucosal surfaces is critical for understanding… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2004
2004
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… Expand
2003
2003
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… Expand
Review
2000
Review
2000
Progenics's rCD4-IgG2 (PRO-542) is a recombinant fusion protein, which has been developed using the company's Universal Antiviral… Expand